The Holon-based company, which utilizes its Unigen AI/ML platform to identify novel drug targets, aims to provide updates on its key therapeutic candidates. Central to the discussion are COM701, an anti-PVRIG antibody currently under evaluation in the MAIA-ovarian trial, and rilvegostomig, a PD-1/TIGIT bispecific antibody developed in partnership with AstraZeneca. Additionally, the presentation will cover GS-0321, a high-affinity antibody licensed to Gilead that blocks the interaction between IL-18 binding protein and IL-18.
In section Releases
Compugen Management to Detail AI-Driven Pipeline at BTIG Conference
Compugen executives will present the company’s latest clinical-stage cancer immunotherapy developments during the virtual BTIG Biotechnology Conference, scheduled for July 28–29, 2026. The sessions will focus on the firm’s proprietary computational platform and the status of its ongoing immuno-oncology research programs.
Interested parties may schedule one-on-one meetings through their BTIG representatives. The company noted that no public replay of the event will be provided following the conclusion of the conference.
Comments (0)
No comments yet. Be the first!